Press Releases

Cookie Notification

We use cookies to collect information about how our website is used and to improve the visitor experience. You can change your browser's cookie settings at any time. Please review our privacy policy for more information. OK

Press Releases

Jan 29, 2018
LONDON, Jan. 29, 2018 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) ("GW" or "the Company"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will announce on 5 February, 2018 its
Jan 24, 2018
— First well-controlled clinical study of cannabidiol in Lennox-Gastaut syndrome, a rare, severe, form of childhood-onset epilepsy that is difficult to treat — — Pharmaceutical formulation of cannabidiol significantly reduced drop seizure frequency in patients with poor seizure control despite the
Dec 29, 2017
LONDON and CARLSBAD, Calif., Dec. 29, 2017 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) ("GW" or "the Company"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced it
Dec 28, 2017
LONDON and CARLSBAD, Calif., Dec. 28, 2017 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) ("GW" or "the Company"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that
Dec 21, 2017
LONDON, Dec. 21, 2017 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) ("GW" or "the Company"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced the appointment of three

Ways to keep up to date with GW